A Placebo-controlled Double-blind, Randomised, Multiple Dose, Dose Escalating Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Miravirsen (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Santaris Pharma
- 04 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jul 2010 Planned end date changed from 1 Aug 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.